1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	MDS-CVI	_	_	NNP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	primarily	_	_	RB	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	data-collection	_	_	NN	_	_	_	_	_
7	tool	_	_	NN	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	when	_	_	WRB	_	_	_	_	_
4	completing	_	_	VBG	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	registry	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	healthcare	_	_	NN	_	_	_	_	_
9	professionals	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	reminded	_	_	VBN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	important	_	_	JJ	_	_	_	_	_
14	actions	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	can	_	_	MD	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	carried	_	_	VBN	_	_	_	_	_
19	out	_	_	RP	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	people	_	_	NNS	_	_	_	_	_
22	with	_	_	IN	_	_	_	_	_
23	risk	_	_	NN	_	_	_	_	_
24	factors	_	_	NNS	_	_	_	_	_
25	such	_	_	JJ	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	older	_	_	JJR	_	_	_	_	_
28	age	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	female	_	_	JJ	_	_	_	_	_
31	sex	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	obesity	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	which	_	_	WDT	_	_	_	_	_
37	increase	_	_	VBP	_	_	_	_	_
38	their	_	_	PRP$	_	_	_	_	_
39	likelihood	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	having	_	_	VBG	_	_	_	_	_
42	CVD	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Activities	_	_	NNS	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	promote	_	_	VB	_	_	_	_	_
4	health	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	prevent	_	_	VB	_	_	_	_	_
7	CVD	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	diagnose	_	_	VB	_	_	_	_	_
11	it	_	_	PRP	_	_	_	_	_
12	at	_	_	IN	_	_	_	_	_
13	earlier	_	_	JJR	_	_	_	_	_
14	stages	_	_	NNS	_	_	_	_	_
15	will	_	_	MD	_	_	_	_	_
16	help	_	_	VB	_	_	_	_	_
17	halt	_	_	VB	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	delay	_	_	VB	_	_	_	_	_
20	disease	_	_	NN	_	_	_	_	_
21	progress	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Healthcare	_	_	NN	_	_	_	_	_
2	professionals	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	those	_	_	DT	_	_	_	_	_
6	working	_	_	VBG	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	primary	_	_	JJ	_	_	_	_	_
9	health	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	particular	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	should	_	_	MD	_	_	_	_	_
14	aim	_	_	VB	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	educate	_	_	VB	_	_	_	_	_
17	at-risk	_	_	JJ	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	lead	_	_	VB	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	healthy	_	_	JJ	_	_	_	_	_
23	lifestyle	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	use	_	_	VB	_	_	_	_	_
26	compression	_	_	NN	_	_	_	_	_
27	stockings	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Due	_	_	JJ	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	increased	_	_	VBN	_	_	_	_	_
4	awareness	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	CVD	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	tendency	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	generally	_	_	RB	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	earlier	_	_	JJR	_	_	_	_	_
14	diagnosis	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	countries	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	disease	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	detected	_	_	VBN	_	_	_	_	_
12	until	_	_	IN	_	_	_	_	_
13	more	_	_	RBR	_	_	_	_	_
14	advanced	_	_	JJ	_	_	_	_	_
15	stages	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	gaps	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	healthcare	_	_	NN	_	_	_	_	_
6	professionals	_	_	NNS	_	_	_	_	_
7	’	_	_	POS	_	_	_	_	_
8	knowledge	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	venous	_	_	JJ	_	_	_	_	_
11	leg	_	_	NN	_	_	_	_	_
12	ulcer	_	_	NN	_	_	_	_	_
13	physiology	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	its	_	_	PRP$	_	_	_	_	_
16	healing	_	_	NN	_	_	_	_	_
17	process	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	partly	_	_	RB	_	_	_	_	_
20	due	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	lack	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	training	_	_	NN	_	_	_	_	_
26	at	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	degree	_	_	NN	_	_	_	_	_
29	level	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	By	_	_	IN	_	_	_	_	_
2	applying	_	_	VBG	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	incorporating	_	_	VBG	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	MDS-CVI	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	patients	_	_	NNS	_	_	_	_	_
9	’	_	_	POS	_	_	_	_	_
10	health	_	_	NN	_	_	_	_	_
11	records	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	healthcare	_	_	NN	_	_	_	_	_
14	professionals	_	_	NNS	_	_	_	_	_
15	will	_	_	MD	_	_	_	_	_
16	find	_	_	VB	_	_	_	_	_
17	it	_	_	PRP	_	_	_	_	_
18	easier	_	_	JJR	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	monitor	_	_	VB	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	disease	_	_	NN	_	_	_	_	_
23	course	_	_	NN	_	_	_	_	_
24	at	_	_	IN	_	_	_	_	_
25	every	_	_	DT	_	_	_	_	_
26	stage	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Above	_	_	IN	_	_	_	_	_
2	all	_	_	DT	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	they	_	_	PRP	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	follow	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	recommendations	_	_	NNS	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	ensure	_	_	VB	_	_	_	_	_
11	correct	_	_	JJ	_	_	_	_	_
12	diagnosis	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	CEAP	_	_	NNP	_	_	_	_	_
3	classification	_	_	NN	_	_	_	_	_
4	system	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	very	_	_	RB	_	_	_	_	_
8	easy	_	_	JJ	_	_	_	_	_
9	method	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	classify	_	_	VB	_	_	_	_	_
12	venous	_	_	JJ	_	_	_	_	_
13	disease	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	reach	_	_	VB	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	reliable	_	_	JJ	_	_	_	_	_
18	diagnosis	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	CVD/CVI	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	population	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clinical	_	_	JJ	_	_	_	_	_
3	part	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	system	_	_	NN	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	obtained	_	_	VBN	_	_	_	_	_
10	simply	_	_	RB	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	observing	_	_	VBG	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	patient	_	_	NN	_	_	_	_	_
15	’s	_	_	POS	_	_	_	_	_
16	legs	_	_	NNS	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	primary	_	_	JJ	_	_	_	_	_
20	care	_	_	NN	_	_	_	_	_
21	setting	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	estimated	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	80	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	population	_	_	NN	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	mildest	_	_	JJS	_	_	_	_	_
13	level	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	symptoms	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	C1	_	_	NN	_	_	_	_	_
18	–	_	_	NN	_	_	_	_	_
19	C2	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	spider	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	varicose	_	_	JJ	_	_	_	_	_
24	veins	_	_	NNS	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	while	_	_	IN	_	_	_	_	_
28	5	_	_	CD	_	_	_	_	_
29	%	_	_	NN	_	_	_	_	_
30	have	_	_	VBP	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	most	_	_	RBS	_	_	_	_	_
33	advanced	_	_	JJ	_	_	_	_	_
34	stages	_	_	NNS	_	_	_	_	_
35	(	_	_	-LRB-	_	_	_	_	_
36	C3	_	_	NN	_	_	_	_	_
37	–	_	_	SYM	_	_	_	_	_
38	C6	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Implementation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	evidence-based	_	_	JJ	_	_	_	_	_
5	MDS-CVI	_	_	NN	_	_	_	_	_
6	would	_	_	MD	_	_	_	_	_
7	result	_	_	VB	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	more	_	_	RBR	_	_	_	_	_
10	reliable	_	_	JJ	_	_	_	_	_
11	data	_	_	NN	_	_	_	_	_
12	collection	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	facilitate	_	_	VB	_	_	_	_	_
15	monitoring	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	specific	_	_	JJ	_	_	_	_	_
19	population	_	_	NN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	observe	_	_	VB	_	_	_	_	_
22	disease	_	_	NN	_	_	_	_	_
23	progression	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	treatments	_	_	NNS	_	_	_	_	_
27	used	_	_	VBN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	their	_	_	PRP$	_	_	_	_	_
31	effectiveness	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	existing	_	_	VBG	_	_	_	_	_
4	level	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	importance	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	therapeutic	_	_	JJ	_	_	_	_	_
12	compression	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	lower	_	_	JJR	_	_	_	_	_
16	limbs	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	it	_	_	PRP	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	unacceptable	_	_	JJ	_	_	_	_	_
21	that	_	_	IN	_	_	_	_	_
22	90	_	_	CD	_	_	_	_	_
23	%	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	patients	_	_	NNS	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	CVI	_	_	NNP	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	Turkey	_	_	NNP	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	54	_	_	CD	_	_	_	_	_
32	%	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	patients	_	_	NNS	_	_	_	_	_
35	with	_	_	IN	_	_	_	_	_
36	venous	_	_	JJ	_	_	_	_	_
37	ulcers	_	_	NNS	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	Spain	_	_	NNP	_	_	_	_	_
40	are	_	_	VBP	_	_	_	_	_
41	not	_	_	RB	_	_	_	_	_
42	given	_	_	VBN	_	_	_	_	_
43	compression	_	_	NN	_	_	_	_	_
44	stockings	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	MDS-CVI	_	_	NNP	_	_	_	_	_
3	will	_	_	MD	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	permit	_	_	VB	_	_	_	_	_
6	health	_	_	NN	_	_	_	_	_
7	managers	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	plan	_	_	VB	_	_	_	_	_
10	interventions	_	_	NNS	_	_	_	_	_
11	according	_	_	VBG	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	venous	_	_	JJ	_	_	_	_	_
15	state	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	population	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	identify	_	_	VB	_	_	_	_	_
21	which	_	_	WDT	_	_	_	_	_
22	quality	_	_	NN	_	_	_	_	_
23	indicators	_	_	NNS	_	_	_	_	_
24	should	_	_	MD	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	applied	_	_	VBN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	People	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	CVI	_	_	NNP	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	poor	_	_	JJ	_	_	_	_	_
7	quality	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	life	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	therefore	_	_	RB	_	_	_	_	_
4	important	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	determine	_	_	VB	_	_	_	_	_
7	how	_	_	WRB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	venous	_	_	JJ	_	_	_	_	_
10	disease	_	_	NN	_	_	_	_	_
11	affects	_	_	VBZ	_	_	_	_	_
12	each	_	_	DT	_	_	_	_	_
13	individual	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Specific	_	_	JJ	_	_	_	_	_
2	instruments	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	available	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	measure	_	_	VB	_	_	_	_	_
7	quality	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	life	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	these	_	_	DT	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	such	_	_	JJ	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	Aberdeen	_	_	NNP	_	_	_	_	_
18	Varicose	_	_	NNP	_	_	_	_	_
19	Vein	_	_	NNP	_	_	_	_	_
20	Questionnaire	_	_	NNP	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	AVVQ	_	_	NNP	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	Chronic	_	_	NNP	_	_	_	_	_
27	Venous	_	_	NNP	_	_	_	_	_
28	Insufficiency	_	_	NNP	_	_	_	_	_
29	Quality	_	_	NNP	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	Life	_	_	NNP	_	_	_	_	_
32	Questionnaire	_	_	NNP	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	CIVIC	_	_	NNP	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	for	_	_	IN	_	_	_	_	_
37	patients	_	_	NNS	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	CVI	_	_	NNP	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	Charing	_	_	NNP	_	_	_	_	_
44	Cross	_	_	NNP	_	_	_	_	_
45	Venous	_	_	NNP	_	_	_	_	_
46	Ulcer	_	_	NNP	_	_	_	_	_
47	Questionnaire	_	_	NNP	_	_	_	_	_
48	for	_	_	IN	_	_	_	_	_
49	patients	_	_	NNS	_	_	_	_	_
50	with	_	_	IN	_	_	_	_	_
51	venous	_	_	JJ	_	_	_	_	_
52	ulcers	_	_	NNS	_	_	_	_	_
53	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	instruments	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	valid	_	_	JJ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	only	_	_	RB	_	_	_	_	_
7	certain	_	_	JJ	_	_	_	_	_
8	languages	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	cultures	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	they	_	_	PRP	_	_	_	_	_
13	therefore	_	_	RB	_	_	_	_	_
14	need	_	_	VBP	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	adapted	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	effective	_	_	JJ	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Non-pharmacological	_	_	JJ	_	_	_	_	_
2	measures	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	essential	_	_	JJ	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	prevention	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	adjuvant	_	_	NN	_	_	_	_	_
10	therapy	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	CVD	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	healthcare	_	_	NN	_	_	_	_	_
15	professionals	_	_	NNS	_	_	_	_	_
16	should	_	_	MD	_	_	_	_	_
17	therefore	_	_	RB	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	aware	_	_	JJ	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	their	_	_	PRP$	_	_	_	_	_
22	existence	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	use	_	_	VB	_	_	_	_	_
25	them	_	_	PRP	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	their	_	_	PRP$	_	_	_	_	_
28	clinical	_	_	JJ	_	_	_	_	_
29	practice	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Recommendations	_	_	NNS	_	_	_	_	_
2	such	_	_	JJ	_	_	_	_	_
3	as	_	_	IN	_	_	_	_	_
4	weight	_	_	NN	_	_	_	_	_
5	loss	_	_	NN	_	_	_	_	_
6	or	_	_	CC	_	_	_	_	_
7	taking	_	_	VBG	_	_	_	_	_
8	regular	_	_	JJ	_	_	_	_	_
9	exercise	_	_	NN	_	_	_	_	_
10	will	_	_	MD	_	_	_	_	_
11	help	_	_	VB	_	_	_	_	_
12	venous	_	_	JJ	_	_	_	_	_
13	return	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	delay	_	_	VB	_	_	_	_	_
16	symptom	_	_	NN	_	_	_	_	_
17	progression	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	MDS	_	_	NNP	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	CVI	_	_	NNP	_	_	_	_	_
5	establishes	_	_	VBZ	_	_	_	_	_
6	minimum	_	_	JJ	_	_	_	_	_
7	quality	_	_	NN	_	_	_	_	_
8	care	_	_	NN	_	_	_	_	_
9	criteria	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	can	_	_	MD	_	_	_	_	_
12	help	_	_	VB	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	guide	_	_	VB	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	purchase	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	necessary	_	_	JJ	_	_	_	_	_
20	services	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_

